LARGE CELL LYMPHOMAS (LCL) EXPRESSING KI-1 (CD30) POSITIVITY: CLINICAL FEATURES OF 15 PATIENTS (MEETING ABSTRACT)

Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

LARGE CELL LYMPHOMAS (LCL) EXPRESSING KI-1 (CD30) POSITIVITY: CLINICAL FEATURES OF 15 PATIENTS (MEETING ABSTRACT)

Proc Annu Meet Am Soc Clin Oncol; 11:A1115 1992. Unique Identifier : AIDSLINE ICDB/92681844
Champagne MA; Klasa RJ; Gascoyne R; Connors JM; British Columbia Cancer Agency, Vancouver, BC, V5Z 4E6, Canada

Abstract: From 7/87 to 6/91, 15 patients (pts), 12 males and 3 females, with Ki-1-positive LCL were identified. Median age at presentation was 41 yr (21-75). Ann Arbor Stages were I (3), II (2), III (4) or IV (6); 11 pts had B symptoms. Eight pts had bulky (greater than 10 cm) disease. Two pts had serum LDH greater than twice normal. Only 3 pts had disease limited to nodal sites. Most common sites of extranodal disease were soft tissue (6) and skin (3). None were HIV or HTLV-1 antibody positive. Immunophenotyping revealed 4 T-cell, 3 B-cell and 8 undefined LCL: all expressed Ki-1 (Ber-H2). Pts were treated with resection alone if LCL was limited to the skin (2), radiotherapy (RT; 1), multiagent chemotherapy, VACOP-B (9) if less than 67 yr or protocols for elderly if older (2), or combination of chemo-RT (1). Complete response was obtained in 11 pts (73%), of which 2 recurred (13%). One then had high-dose chemotherapy and autologous BMT, remaining in remission since. One died without evidence of LCL. Two achieved partial remission, 1 rendered disease-free after additional RT. Four pts (27%) have died for an overall 4-yr survival of 73% with a median follow-up of 19 mo. Two pts with small localized skin presentation have remained disease-free after resection only. In our experience, Ki-1 + LCL more frequently presents with bulky disease and extranodal extension, but has a prognosis at least as good as other large cell lymphomas similarly treated at our institution.

Keywords: Aged Antigens, CD/*ANALYSIS Antigens, Neoplasm/*ANALYSIS Bleomycin/THERAPEUTIC USE Bone Marrow Transplantation Combined Modality Therapy Cyclophosphamide/THERAPEUTIC USE Doxorubicin/THERAPEUTIC USE Etoposide/THERAPEUTIC USE Female Human Lymphatic Metastasis Lymphoma, Large-Cell/DRUG THERAPY/*IMMUNOLOGY/RADIOTHERAPY/ SURGERY Male Middle Age Prednisone/THERAPEUTIC USE Vincristine/THERAPEUTIC USE ABSTRACT
921030
M92A1029

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .